Vascular Biogenics Ltd. (VBLT)
(Delayed Data from NSDQ)
$1.28 USD
+0.01 (0.79%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.28 USD
+0.01 (0.79%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline
by Zacks Equity Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -25.00% and -66.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 27.78% and -40.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Enters Oversold Territory
by Zacks Equity Research
Vascular Biogenics Ltd. (VBLT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options
by Zacks Equity Research
Surging implied volatility makes Vascular Biogenics (VBLT) stock lucrative to the option traders.
Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vascular Biogenics (VBLT) stock based on the movements in the options market lately.
What Falling Estimates & Price Mean for Vascular Biogenics (VBLT)
by Zacks Equity Research
Vascular Biogenics (VBLT) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%
by Zacks Equity Research
Vascular Biogenics (VBLT) shares rose over 5% in the last trading session.